0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Patient Page |

Pulmonary Embolism FREE

Jill M. Merrigan, BA; Gregory Piazza, MD, MS; Cassio Lynm, MA; Edward H. Livingston, MD
JAMA. 2013;309(5):504. doi:10.1001/jama.2012.145097.
Text Size: A A A
Published online

A pulmonary embolism (PE) is a blood clot that blocks the blood vessels supplying the lungs. The clot (embolus) most often comes from the leg veins and travels through the heart to the lungs. When the blood clot lodges in the blood vessels of the lung, it may limit the heart's ability to deliver blood to the lungs, causing shortness of breath and chest pain, and, in serious cases, death. The US surgeon general estimates that 100 000 to 180 000 deaths occur from PE each year in the United States and identifies PE as the most preventable cause of death among hospitalized patients. The January 9, 2013, issue of JAMA contains an article about management of PE.

RISK FACTORS

  • Genetic and acquired tendencies to develop blood clots

  • Pregnancy; use of birth control pills or hormone therapy

  • Obesity

  • Smoking

  • Cancer

  • Medical illnesses including heart disease, lung disease, and kidney disease

  • Older age

  • Recent surgery, trauma, hospitalization, or prolonged bed rest

SIGNS AND SYMPTOMS

  • Shortness of breath

  • Chest discomfort

  • Coughing up blood

  • Palpitations

  • Dizziness and fainting

  • Leg swelling and discomfort

TREATMENT

Anticoagulants (commonly called blood thinners) are the main treatment for pulmonary embolism and work by preventing new blood clots from forming while the body breaks down the pulmonary embolism. Options for anticoagulation in patients with PE include intravenous heparin and injectable enoxaparin, dalteparin, and fondaparinux. Oral anticoagulants for PE include warfarin and rivaroxaban. Most patients with PE receive at least 6 months of anticoagulation treatment. Many patients are advised to continue anticoagulation treatment for longer than 6 months, sometimes lifelong, if their risk of recurrent PE is high.

For some patients with large or massive pulmonary embolism, more aggressive therapy is required. These treatments include clot-dissolving medications, invasive procedures to remove the embolus with catheters or surgery, and implantation of a filter device to catch free blood clots before they reach the heart.

Treating risk factors for pulmonary embolism is a critical step in preventing future blood clots. Lifestyle changes such as regular exercise, a heart-healthy diet, and smoking cessation are important steps in reducing risk.

FOR MORE INFORMATION

INFORM YOURSELF

To find this and previous JAMA Patient Pages, go to the Patient Page index on JAMA 's website at www.jama.com. Many are available in English and Spanish.

The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 312/464-0776.

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Topic: VASCULAR DISEASE

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Spanish Patient Page: Embolia pulmonar

Supplemental Content

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
CME Related by Topic
PubMed Articles
JAMAevidence.com

Users' Guides to the Medical Literature
Thromboembolism or Acute Pulmonary Embolism

Users' Guides to the Medical Literature
Table 9.2-3 Refuted Evidence From Observational Studiesa